CJC-1295 Peptide vs DAC: Research Comparison (2026)

Qualified researchers studying growth-hormone-releasing pathways often hit the same early question: which form of the CJC-1295 peptide fits their experimental design, and how do the two variants actually differ in a controlled lab setting? This guide breaks down CJC-1295 with DAC versus without DAC, outlines dosage considerations used in published research, and explains what to look for when sourcing research-grade material. At PeptideValidation.com, CJC-1295 is supplied as a 5 mg lyophilized powder intended exclusively for laboratory research, not for human or veterinary use.

What Is CJC-1295? A Clear Definition for Researchers

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH) consisting of 30 amino acids. It binds to GHRH receptors in the pituitary gland and stimulates growth hormone secretion. Two research variants exist: CJC-1295 without DAC (also called Modified GRF 1-29) and CJC-1295 with DAC, which has a significantly extended half-life due to the Drug Affinity Complex modification.

CJC-1295 is a synthetic peptide derived from the first 29 amino acids of endogenous GHRH, with four amino acid substitutions that improve stability against enzymatic degradation. In its base form (no DAC), the peptide has a half-life of roughly 30 minutes, making it structurally closer to native GHRH.

The DAC (Drug Affinity Complex) modification attaches a lysine residue with a maleimidoproprionic acid linker. This allows the peptide to bind covalently to circulating serum albumin, extending its half-life to approximately 6 to 8 days in preclinical models. That single structural difference defines almost every experimental variable that separates the two forms.

Neither variant is a steroid. Researchers sometimes ask "is CJC-1295 a steroid?", the answer is no. It is a peptide hormone secretagogue, meaning it stimulates the pituitary to release GH rather than introducing an exogenous hormone directly. The distinction matters for experimental design and for how results are interpreted downstream.

For labs at PeptideValidation.com working in endocrine or metabolic signalling research, understanding this structural difference is the first step toward choosing the right compound and the right study protocol.

CJC-1295 With DAC vs Without DAC: Side-by-Side Comparison

The core difference between CJC-1295 with DAC and without DAC is pharmacokinetic profile. Without DAC, the peptide clears in roughly 30 minutes and produces a sharp, pulsatile GH release. With DAC, albumin binding extends its activity to 6-8 days, producing a broader, sustained GH elevation. Researchers choose between them based on whether their model requires pulsatile or steady-state GH signalling.

Here is a direct comparison of the two forms across variables that matter most in controlled research:

Feature	CJC-1295 No DAC	CJC-1295 DAC
Common alias	Modified GRF 1-29	CJC-1295 with DAC
Half-life	~30 minutes	~6 to 8 days
GH release pattern	Pulsatile (mimics natural pulse)	Sustained (blunted pulse, elevated baseline)
Dosing frequency in studies	Multiple times per day or per week	Once or twice per week
Albumin binding	No	Yes (via DAC linker)
Typical study application	Acute GH secretion models	Chronic GH elevation models

For models studying acute GH pulsatility, no-DAC is the cleaner tool. The short half-life means researchers can time measurements precisely around dosing events and observe a signal that resembles physiological GH release.

For longer-duration metabolic or endocrine studies where maintaining a sustained GH environment is the goal, the CJC-1295 DAC peptide provides convenience and consistency. Fewer administrations reduce handling variables, which can improve reproducibility across a multi-week study.

The tradeoff with DAC is that the blunted pulsatility may not model natural GH physiology well. If your endpoint depends on observing normal GH pulsatile architecture, that distinction is worth factoring into your design before you order.

CJC-1295 Dosage Considerations in Published Research

Published preclinical studies using CJC-1295 have employed doses ranging from 30 mcg/kg to 1 mg/kg depending on the species, model, and endpoint. CJC-1295 with DAC dosage in human pharmacokinetic studies has ranged from 30 mcg/kg to 120 mcg/kg administered once weekly or biweekly. Researchers should consult primary literature and institutional protocols before designing any dosing schedule.

Dosage in CJC-1295 research is not one-size-fits-all. The original 2006 pharmacokinetic study by Jetley et al. used single intravenous and subcutaneous doses ranging from 30 to 120 mcg/kg and found that GH levels remained elevated for 6 days or longer in subjects receiving the DAC form. That study is still the most-cited reference point for CJC-1295 with DAC dosage design.

For no-DAC forms, rodent studies have used doses from 30 mcg/kg up to 300 mcg/kg, often administered twice daily. The goal in those protocols is typically to maintain GH pulsatility without saturating receptors, so dose spacing matters as much as the dose itself.

A few practical points for lab teams designing CJC-1295 peptide dosage protocols:

• Match the dosing interval to the half-life of the specific form you are using.
• Use body-weight-adjusted dosing when comparing across species or cohort sizes.
• Define your GH measurement window relative to peak peptide activity (roughly 2 hours post-administration for no-DAC).
• Consider IGF-1 as a secondary marker, since many published studies use it as a downstream readout of GH signalling.

None of this constitutes clinical advice. It is a summary of what peer-reviewed literature has documented in controlled laboratory settings.

Evaluating CJC-1295 Peptide Research Grade: What a Good COA Shows

A research-grade CJC-1295 Certificate of Analysis (COA) should include: HPLC purity (typically 98% or higher), mass spectrometry identity confirmation matching the expected molecular weight of approximately 3647 Da, batch and lot numbers, manufacturing date, and recommended storage conditions (-20 degrees C or colder for lyophilized powder).

Not all COAs are created equal. A one-page document showing a single purity number is not sufficient for serious laboratory work. Researchers sourcing CJC-1295 peptide should look for COAs that include both HPLC chromatography traces and MS spectra, not just summary numbers.

HPLC purity of 98% or above is the standard benchmark for research-grade peptide compounds. Mass spectrometry should confirm the molecular weight within a narrow tolerance, for CJC-1295 without DAC (Modified GRF 1-29), the expected molecular weight is approximately 3367 Da; for the DAC form, approximately 3647 Da. Any deviation outside instrument tolerance warrants follow-up with the supplier.

PeptideValidation.com evaluates vendors against a checklist that includes transparent batch sourcing, third-party analytical testing, and documented quality management systems. When CJC-1295 is supplied as a 5 mg lyophilized powder, the lyophilized format matters too: it is more stable during shipping and storage than reconstituted solutions, and a well-prepared lyophilized peptide should show less than 0.5% moisture content when tested.

If a vendor cannot produce a batch-specific COA on request, that is a clear signal to look elsewhere. Generic or undated COAs suggest that testing was not performed on the material you are actually receiving.

CJC-1295 Peptide Benefits in Research Contexts

Research examining CJC-1295 peptide benefits has focused on its ability to stimulate endogenous GH release, increase IGF-1 concentrations in preclinical models, and sustain those effects over extended periods when the DAC form is used. These properties make it a useful research tool for studying GH-axis signalling, metabolic regulation, and anabolic pathway activation in controlled laboratory settings.

The phrase "CJC-1295 peptide benefits" appears frequently in research literature, but context matters. In a laboratory setting, the relevant benefits are about the compound's utility as a research tool, not therapeutic outcomes.

From a signalling research perspective, CJC-1295 is useful because it:

• Produces consistent, dose-dependent GH secretion in preclinical models.
• Stimulates downstream IGF-1 production, giving researchers a measurable secondary endpoint.
• Allows investigation of both pulsatile (no-DAC) and sustained (DAC) GH signalling with the same core peptide sequence.
• Has a well-characterized binding profile at the GHRH receptor, which simplifies mechanistic interpretation.
• Remains stable in lyophilized form, reducing compound degradation as an experimental confounder.

Researchers in endocrine and metabolic studies have used CJC-1295 to build models of GH deficiency correction, study the interaction between GH and insulin signalling, and examine anabolic pathway dynamics in tissue cultures. The compound's predictable kinetics make it easier to design clean experimental controls compared to direct GH administration.

That said, CJC-1295 is a research compound with a specific application scope. Its utility depends entirely on the rigor of the experimental design surrounding it.

Potential Adverse Signals Noted in Research: CJC-1295 Side Effects Data

Preclinical and early-phase studies have noted several adverse signals associated with CJC-1295, including transient flushing, water retention, and injection-site reactions. At higher doses in animal models, hypoglycemia and mild increases in prolactin have been observed. These signals inform how researchers design safety monitoring in longer-duration studies.

Understanding CJC-1295 side effects data is important for researchers designing study safety protocols, even in preclinical settings.

The 2006 pharmacokinetic study noted mild flushing and facial redness in some subjects within minutes of administration. These acute vasodilatory responses appear dose-dependent and transient, typically resolving within 30 minutes. Water retention was also observed and has been attributed to the GH-mediated increase in renal sodium reabsorption.

In rodent models using higher dose ranges (above 300 mcg/kg), some studies have reported transient hypoglycemia, likely reflecting the downstream insulin-sensitizing effects of elevated IGF-1. Prolactin increases, though modest, have also been documented in some rodent data, which is relevant for studies where prolactin is a confounding variable.

For lab teams, the practical implication is to include glucose monitoring and relevant hormonal panels as part of the study design when working with CJC-1295 at higher doses. Injection-site histology is also worth including in longer studies using the DAC form, since its extended residence time means repeated local exposure at the same site.

None of this is intended as a safety warning for human use. CJC-1295 is a research compound, and these signals are documented here to help laboratories build better-controlled experimental designs, not to characterize clinical risk.

How to Compare CJC-1295 Vendors: Price, Purity, and Certification

When comparing CJC-1295 peptide suppliers, researchers should evaluate: COA completeness (HPLC + MS), third-party testing independence, batch traceability, lyophilized vs solution format, price per milligram relative to stated purity, and vendor certification standards. Price alone is a poor proxy for quality in the research peptide market.

"CJC 1295 peptide price" is one of the most common search terms in this space, and understandably so. Research budgets are real constraints. But price-per-milligram comparisons only make sense when purity is held constant. A 95% pure compound at a lower price may introduce more experimental noise than a 98%+ compound at a higher price, and that noise has a cost of its own.

Here are the criteria that matter most when comparing vendors:

COA completeness. Does the COA include HPLC chromatograms and MS spectra, or just summary numbers? Batch-specific documentation should be available on request or download before purchase.

Third-party testing. Is the testing done in-house or by an independent laboratory? Independent testing reduces conflicts of interest and increases result reliability.

Format and stability. Lyophilized 5 mg powder is the preferred format for research use. It ships and stores more reliably than pre-reconstituted vials, and it gives the researcher control over reconstitution buffer and concentration.

Certification standards. PeptideValidation.com reviews vendors against objective quality criteria including documented quality management systems, sourcing transparency, and responsive technical support. These standards exist because the research peptide marketplace varies widely in quality.

Regulatory clarity. A credible vendor states clearly that CJC-1295 is for research use only. Any vendor making health or performance claims about the compound is not operating within appropriate research-compound norms.

For researchers ready to go deeper on compound verification, quality standards, and what separates reliable suppliers from questionable ones, the full research guide at PeptideValidation.com covers the complete picture.

Frequently asked questions

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 without DAC (Modified GRF 1-29) has a half-life of roughly 30 minutes and produces a short, pulsatile GH release. CJC-1295 with DAC binds to serum albumin via a Drug Affinity Complex linker, extending its half-life to approximately 6 to 8 days and producing a sustained GH elevation. Researchers choose between them based on whether their study model requires pulsatile or steady-state GH signalling.

Is CJC-1295 a steroid?

No. CJC-1295 is a synthetic peptide analogue of growth-hormone-releasing hormone (GHRH). It is a peptide secretagogue that stimulates the pituitary gland to release endogenous growth hormone. It is not a steroid, does not share the steroidal ring structure, and has a completely different mechanism of action from anabolic or corticosteroid compounds.

What dosage of CJC-1295 is used in research studies?

Published preclinical studies have used CJC-1295 doses ranging from 30 mcg/kg to 300 mcg/kg depending on the species and endpoint. Early human pharmacokinetic studies used 30 to 120 mcg/kg for the DAC form, administered once or twice weekly. Dosage should always be determined by the study design, relevant literature, and institutional protocols. CJC-1295 is for research use only.

What side effects have been noted in CJC-1295 research?

Published studies have documented transient flushing, water retention, and injection-site reactions. At higher doses in preclinical animal models, mild hypoglycemia and modest prolactin increases have been observed. These adverse signals are relevant for laboratory safety protocol design. CJC-1295 is a research compound and is not approved or intended for human therapeutic use.

What should a CJC-1295 Certificate of Analysis include?

A research-grade CJC-1295 COA should include HPLC purity results (98% or higher is the standard benchmark), mass spectrometry identity confirmation matching the expected molecular weight, batch and lot numbers, manufacturing date, and storage conditions. Both HPLC chromatograms and MS spectra should be available as supporting documentation, not just summary purity figures.

How does CJC-1295 compare to direct growth hormone administration in research?

CJC-1295 stimulates the pituitary to release endogenous GH rather than introducing exogenous GH directly. This indirect mechanism preserves some degree of natural regulatory feedback, which is useful for models where the GH axis architecture matters. Direct GH administration bypasses pituitary regulation entirely. Researchers choose between the two approaches based on which pathway their study is designed to interrogate.

Related in this series

• CJC-1295 Peptide vs DAC Form: Which to Research